(Q37780222)

23 August 2017

1 reference

title

IFN-beta pharmacogenomics in multiple sclerosis (English)

1 reference

23 August 2017

0 references

1 reference

Koen Vandenbroeck

1

1 reference

PubMed ID

20712530

23 August 2017

Elena Urcelay

series ordinal

2

1 reference

PubMed ID

20712530

23 August 2017

Manuel Comabella

series ordinal

3

1 reference

23 August 2017

1 August 2010

1 reference

23 August 2017

1 reference

23 August 2017

11

1 reference

23 August 2017

8

1 reference

23 August 2017

1137-1148

1 reference

MRI as a marker for disease heterogeneity in multiple sclerosis.

23 August 2017

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Management of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

How cells respond to interferons revisited: from early history to current complexity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Link protein has greater affinity for versican than aggrecan

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

CLAC binds to amyloid beta peptides through the positively charged amino acid cluster within the collagenous domain 1 and inhibits formation of amyloid fibrils

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Characterization of the Alzheimer's disease-associated CLAC protein and identification of an amyloid beta-peptide-binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Genetic association to the amyloid plaque associated protein gene COL25A1 in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Association of the calpain/calpastatin network with subcellular organelles

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Organization of the presynaptic active zone by ERC2/CAST1-dependent clustering of the tandem PDZ protein syntenin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

A novel haplotype-sharing approach for genome-wide case-control association studies implicates the calpastatin gene in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Disruption of the neuronal PAS3 gene in a family affected with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Interacting haplotypes at the NPAS3 locus alter risk of schizophrenia and bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Targeting and clustering citron to synapses.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Antiviral actions of interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

GPC4, the gene for human K-glypican, flanks GPC3 on xq26: deletion of the GPC3-GPC4 gene cluster in one family with Simpson-Golabi-Behmel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Online access to CGH data of DNA sequence copy number changes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Role for amplification and expression of glypican-5 in rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Expression of the cell surface proteoglycan glypican-5 is developmentally regulated in kidney, limb, and brain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Localisation of specific heparan sulfate proteoglycans during the proliferative phase of brain development.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

When sugars guide axons: insights from heparan sulphate proteoglycan mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Heparan sulfate proteoglycans and the emergence of neuronal connectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Extracellular sugar modifications provide instructive and cell-specific information for axon-guidance choices

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Constitutive release of alpha4 type V collagen N-terminal domain by Schwann cells and binding to cell surface and extracellular matrix heparan sulfate proteoglycans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Glypican-1 and alpha4(V) collagen are required for Schwann cell myelination

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Specific modification of heparan sulphate is required for normal cerebral cortical development

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Regional manifestations and control of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Heparanase, a potential regulator of cell-matrix interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Genetic polymorphisms, their allele combinations and IFN-beta treatment response in Irish multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Pharmacogenetics of MXA SNPs in interferon-beta treated multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

HLA class II and response to interferon-beta in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

HLA class I and II alleles and response to treatment with interferon-beta in relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Transcription-based prediction of response to IFNbeta using supervised computational methods

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

A Markov chain Monte Carlo technique for identification of combinations of allelic variants underlying complex diseases in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Pharmacogenomics of Type I interferon therapy: a survey of response-modifying genes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Microarray analysis identifies interferon beta-regulated genes in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Microarray analysis identifies a set of CXCR3 and CCR2 ligand chemokines as early IFNbeta-responsive genes in peripheral blood lymphocytes in vitro: an implication for IFNbeta-related adverse effects in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Genome-wide network analysis reveals the global properties of IFN-beta immediate transcriptional effects in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Migration of multiple sclerosis lymphocytes through brain endothelium.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Expression of the chemokine receptors CXCR1 and CXCR2 in rat oligodendroglial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Expression of the receptors for the C5a anaphylatoxin, interleukin-8 and FMLP by human astrocytes and microglia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon β: Implications for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-β

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

Evidence for a cross-talk between human neutrophils and Th17 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.108

21 January 2018

Identifiers

DOI

10.2217/PGS.10.108

1 reference

23 August 2017

1 reference

PubMed ID

20712530